Top Page
Hikma Pharmaceuticals
(LSE:HIK)
Hikma Pharmaceuticals (HIK) vs. S&P 500 (SPY)
Hikma Pharmaceuticals Business Overview & Revenue Model
Hikma Pharmaceuticals Financial Statement Overview
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 3.02B | 2.88B | 2.52B | 2.55B | 2.34B | 2.21B | Gross Profit |
| 1.45B | 1.41B | 1.26B | 1.30B | 1.21B | 1.10B | EBIT |
| 661.00M | 367.00M | 591.00M | 634.00M | 540.00M | 486.00M | EBITDA |
| 844.00M | 791.00M | 485.00M | 744.00M | 654.00M | 584.00M | Net Income Common Stockholders |
| 285.00M | 190.00M | 188.00M | 421.00M | 431.00M | 486.00M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 205.00M | 229.00M | 292.00M | 450.00M | 347.00M | 465.00M | Total Assets |
| 4.68B | 4.68B | 4.47B | 4.37B | 4.13B | 3.93B | Total Debt |
| 1.19B | 1.19B | 1.28B | 846.00M | 932.00M | 685.00M | Net Debt |
| 986.00M | 986.00M | 1.01B | 420.00M | 609.00M | 243.00M | Total Liabilities |
| 2.47B | 2.47B | 2.32B | 1.91B | 1.99B | 1.80B | Stockholders Equity |
| 2.20B | 2.20B | 2.13B | 2.45B | 2.13B | 2.12B |
| Cash Flow | Free Cash Flow | ||||
| 430.00M | 439.00M | 392.00M | 493.00M | 292.00M | 353.00M | Operating Cash Flow |
| 584.00M | 608.00M | 530.00M | 638.00M | 464.00M | 472.00M | Investing Cash Flow |
| -320.00M | -333.00M | -607.00M | -238.00M | -283.00M | -151.00M | Financing Cash Flow |
| -291.00M | -337.00M | -58.00M | -287.00M | -298.00M | -155.00M |
Hikma Pharmaceuticals Technical Analysis
Hikma Pharmaceuticals Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | £155.19B | 28.18 | 17.43% | 2.45% | 14.82% | 14.98% | |
77 Outperform | £4.06B | 14.42 | 15.79% | 3.38% | 5.83% | 83.35% | |
70 Outperform | £53.62B | 20.94 | 19.06% | 4.71% | 3.46% | -48.06% | |
48 Neutral | $6.46B | 1.17 | -48.25% | 2.67% | 19.50% | 0.61% | |
47 Neutral | £1.14B | ― | ― | 8.69% | -1568.57% |
Hikma Pharmaceuticals Corporate Events
Hikma Pharmaceuticals PLC announced the granting of discretionary share awards under its 2023 Long Term Incentive Plan (LTIP) and Deferred Bonus Plan (DBP) to key managerial personnel. These awards, which are conditional on continued employment and performance criteria, are designed to align the interests of the company’s leadership with its long-term strategic goals, potentially impacting the company’s operational focus and stakeholder value.
Spark’s Take on GB:HIK Stock
According to Spark, TipRanks’ AI Analyst, GB:HIK is a Outperform.
Hikma Pharmaceuticals’ strong financial performance and positive corporate events are major strengths, driving a robust stock score. The reasonable valuation and attractive dividend yield further enhance its appeal. However, technical indicators suggest caution due to a bearish trend, which tempers the overall outlook.
To see Spark’s full report on GB:HIK stock, click here.
Hikma Pharmaceuticals announced a transaction involving the disposal of shares by Victoria Hull, a Non-Executive Director of the company. The transaction, which involved the sale of 2,777 ordinary shares at a price of £18.00 each, was conducted on the London Stock Exchange, totaling £49,986. This notification is part of compliance with the EU Market Abuse Regulation, reflecting transparency in managerial transactions.
Spark’s Take on GB:HIK Stock
According to Spark, TipRanks’ AI Analyst, GB:HIK is a Outperform.
Hikma Pharmaceuticals’ strong financial performance and positive corporate events are major strengths, driving a robust stock score. The reasonable valuation and attractive dividend yield further enhance its appeal. However, technical indicators suggest caution due to a bearish trend, which tempers the overall outlook.
To see Spark’s full report on GB:HIK stock, click here.
Hikma Pharmaceuticals has released its 2024 Annual Report and Accounts alongside the Notice of the 2025 Annual General Meeting. These documents are now accessible to shareholders via the company’s website and the UK National Storage Mechanism, reflecting Hikma’s commitment to transparency and regulatory compliance. This announcement underscores Hikma’s ongoing efforts to maintain strong communication with its stakeholders and adhere to financial reporting standards, potentially impacting investor confidence and market perception.
Hikma Pharmaceuticals announced the vesting of conditional share awards for several key executives under its Executive Incentive Plan. This move reflects the company’s ongoing commitment to rewarding its leadership team, potentially enhancing managerial stability and aligning executive interests with shareholder value. The shares were acquired without any cost and retained by the executives, indicating confidence in the company’s future performance.
Hikma Pharmaceuticals reported a strong financial performance for 2024, with a 10% growth in core revenue and a 67% increase in reported operating profit. The company’s strategic acquisitions, such as Xellia Pharmaceuticals’ US business, and new partnerships have bolstered its market position, particularly in the injectables and generics segments. Hikma’s continued investment in R&D and business development is expected to drive future growth, with a positive outlook for 2025, including projected revenue growth of 4% to 6%. The company’s robust balance sheet and increased dividend reflect confidence in its future prospects.
Hikma Pharmaceuticals has announced that it will release its financial results for the year ended 31 December 2024 on 26 February 2025. This announcement is significant as it provides insights into the company’s financial health and operational performance, which could impact its market positioning and stakeholder confidence.